Rashmi Kumar, MD
Gastroenterology · Irvine, CANPI 1396007068
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (50.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Pfizer at 52.8% of the total. Reporting peaked in 2021 at $80,070 and has fallen 52.7% since, to $37,880 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $533.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$84K
- Johnson & Johnson$71K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$420
- Lilly USA, LLC$252
- Bristol Myers Squibb$165
- plus $615 from 15 others
What the payments were for
- Speaking & faculty fees$67,61643%
- Grants$80,00050%
- Travel & lodging$4,2223%
- Food & beverage$6,8234%
- Education$2260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 36 | $83,957 |
| Johnson & Johnson | 93 | $71,012 |
| AbbVie(2 entities) | 100 | $2,466 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $420 |
| Lilly USA, LLC | 10 | $252 |
| Bristol Myers Squibb | 10 | $165 |
| Sanofi | 5 | $140 |
| Celltrion USA Inc. | 5 | $133 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Boston Scientific | 2 | $42 |
| Braintree Laboratories, Inc. | 2 | $35 |
| Fresenius Kabi USA, LLC | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Merck | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Shionogi Inc | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Dynavax Technologies Corporation | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$158,887 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 28 | $16,484 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 21 | $1,163 |
| Pantoprazole Sodium | 19 | $233 |
| Omeprazole | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Irvine
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
- Kenneth BinmoellerSan Francisco$507K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.